Tag: TERRANOVA

1. Two complementary phase 3 clinical trials randomized patients with moderate-to-severe COPD to receive either benralizumab or a placebo and found that the trial agent did not lead to a significant reduction in chronic obstructive pulmonary disease (COPD) exacerbation rates. 2. Safety outcomes were comparable between groups. Evidence Rating Level:...